Oncology Molecular Diagnostics Market Report 2026

Oncology Molecular Diagnostics Market Overview

• Oncology Molecular Diagnostics market size has reached to $5.65 billion in 2025 • Expected to grow to $10.13 billion in 2030 at a compound annual growth rate (CAGR) of 12.4% • Growth Driver: Rising Demand For Personalized Medicine Driving Growth In The Oncology Molecular Diagnostics Market • Market Trend: Revolutionizing Oncology Molecular Diagnostics Through Advanced Genomics Technology • North America was the largest region in 2025 and Western Europe is the fastest growing region.

What Is Covered Under Oncology Molecular Diagnostics Market?

The oncology molecular diagnostics refers to a procedure for diagnosing cancers and related services. Molecular diagnostics are tests that diagnose genetic information, proteins, or related molecules and provide health or disease information. The main products in oncology molecular diagnostics market are instruments, reagents, and others. The oncology molecular diagnostics instruments are used for diagnosing cancer. The various technologies involved are polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermic nucleic acid amplification technology (INNAT), chips and microarrays, sequencing, mass spectroscopy, transcription-mediated amplification (TMA), and others. These are used by various end-users, such as hospitals, diagnostic centers, academic and research institutes, and others.

What Is The Oncology Molecular Diagnostics Market Growth Forecast?

The oncology molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $10.13 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to precision oncology adoption, liquid biopsy advancements, personalized treatment demand, AI-driven data interpretation, emerging market penetration. Major trends in the forecast period include growth in companion diagnostics, rising use of liquid biopsy, expansion of biomarker-based testing, increasing cancer screening programs, demand for early and accurate cancer detection.

Global Oncology Molecular Diagnostics Market Segmentation

1) By Product: Instruments, Reagents, Other Products 2) By Technology: Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips And Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies 3) By End User: Hospitals, Diagnostic Centers, Academic And Research Institutes, Other End Users Subsegments: 1) By Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, Microarray Platforms, Fluorescence In Situ Hybridization (FISH) Instruments 2) By Reagents: DNA And RNA Extraction Kits, PCR Reagents And Kits, NGS Library Preparation Kits, Diagnostic Assay Reagents 3) By Other Products: Software For Data Analysis And Interpretation, Quality Control And Calibration Products, Consumables, For Molecular Testing, Biomarkers For Oncology Testing

What Is The Driver Of The Oncology Molecular Diagnostics Market?

The increasing demand for personalized medicine is expected to propel the growth of the oncology molecular diagnostics market going forward. Personalized medicine refers to an innovative approach to medical treatment and healthcare that tailors medical decisions, practices, interventions, and drug therapies to the individual patient. Oncology molecular diagnostics are instrumental in the era of personalized medicine for cancer patients as they provide customized treatment plans, optimized drug selection, and more precise, effective, and individualized treatment strategies, ultimately improving patient outcomes and quality of life. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the oncology molecular diagnostics industry.

Key Players In The Global Oncology Molecular Diagnostics Market

Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.

Global Oncology Molecular Diagnostics Market Trends and Insights

Major companies operating in the oncology molecular diagnostics market are focusing on advancing genomics technologies such as next-generation cancer genome sequencing, computational analytics, and innovative tumor modeling to improve early cancer detection, mutation identification, and personalized treatment strategies. These advancements enhance diagnostic precision, reduce turnaround times, and support the growing demand for localized, high-accuracy molecular testing. For instance, in May 2024, OncoHelix-CoLab, a Canada-based precision oncology provider specializing in genomic and immunologic profiling, advanced molecular diagnostics, and immune-profile testing, launched a state-of-the-art laboratory at Burjeel Medical City in the UAE. Developed through a collaboration between Burjeel Holdings and OncoHelix, the facility strengthens regional diagnostic capabilities by enabling complex molecular and immunology tests to be conducted locally rather than sent abroad. Its specialized offerings include advanced assays for multiple cancers, such as prostate cancer, supported through partnerships like its collaboration with Nanostics for the ClarityDX Prostate test.

What Are Latest Mergers And Acquisitions In The Oncology Molecular Diagnostics Market?

In June 2023, INEX Innovate Pte Ltd, a Singapore based molecular diagnostic technology company, acquired Yourgene Health (Taiwan) Co., Ltd. for an undisclosed amount. With this acquisition, INEX Innovate’s aim is to enhance INEX's capabilities in fetal health, oncology research and development, and bioinformatics. Yourgene Health is a Taiwan based genomics company, an international molecular diagnostics group that is extending its genetic testing to include oncology.

Regional Outlook

North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Oncology Molecular Diagnostics Market?

The oncology molecular diagnostics market includes revenues earned by oncology molecular diagnostics tools and kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.